Obesity Treatment Market Analysis, Share, Size, Trends, Market Growth and Segment Forecasts To 2027

Market Research Future (MRFR), while discussing the possibilities of the global market for obesity treatment, predicted rise by 17.7% during the forecast period of 2020 to 2027

 

Overview:

Market Research Future (MRFR), while discussing the possibilities of the global market for obesity treatment, predicted rise by 17.7% during the forecast period of 2020 to 2027. This growth will depend a lot on the changes in weight loss and weight management market. 

Drivers and Restraints:

The obesity treatment market analysis will depend on aspects like the rising awareness, a surge in the number of health-conscious people, better inclusion rate for latest technologies, a hike in investment for research and development, innovations and their speedy approval, awaiting products in the pipeline, a surge in disposable income, changing food habits, and others. In developing countries, this growth is getting backed by strategies launched by top brands to ensure their expansion. 

However, the obesity treatment market share may find some roadblocks in the form of a sedentary lifestyle that has been enforced on people by rapidly increasing industrialization and urbanization. 

Segmentation:

The global obesity treatment market analysis has been studied by MRFR on the basis of a type, diagnosis, treatment, and end-user. These segments and data in them are expected to facilitate the decision-making process for the future.

By type, the obesity treatment market has been studied on the basis of food obesity, anxiety obesity, inactivity obesity, atherogenic obesity, venous obesity, and gluten obesity. 

By diagnosis, the report containing details of the obesity treatment market has been segmented into physical examination, blood tests, and others. The blood tests segment includes thyroid test, liver function test, cholesterol test, and others. The physical examination segment comprises blood pressure measurement, heart rate measurement, and others. 

By treatment, the study on the global obesity treatment market analysis includes surgery, medication, lifestyle changes, and others. The medication segment has been studied on the basis of lorcaserin, orlistat, liraglutide, phentermine and topiramate, and others. The surgery segment includes Laparoscopic Adjustable Gastric Banding (LAGB), gastric bypass surgery, biliopancreatic diversion, gastric sleeve, gastric sleeve, and others. 

By end-user, the report on the physical therapy for obesity includes clinics, pharmacies, hospitals, and others.

Regional Analysis:

The Americas is slated to take the lead of the global market during the forecast period by maintaining a steady flow of investment, increasing awareness, and funding various research projects. The US and Canada would impact the market the most. In Asia Pacific, the growth would experience traction from rising disposable income. 

Competitive Landscape:

Arena Pharmaceuticals, Inc. (U.S.), VIVUS, Inc. (U.S.), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc. (U.S.), F. Hoffmann-La Roche, Ltd. (Switzerland), Cousin Biotech (France), EnteroMedics, Inc. (U.S.), Allergan (Republic of Ireland), Olympus Corporation (Japan), Medtronic (U.S.), USGI Medical, Inc. (U.S.), Johnson Johnson Services, Inc. (U.S.), Covidien plc (Republic of Ireland), Mediflex Surgical Products (U.S.), and others are some of the major companies impacting the obesity treatment market trends and outcomes. 

Industry News:

In June 2020, researchers from the Pennington Biomedical Research Center in Baton Rouge, LA, declared that they had discovered BAM15. This is a protein that can have a significant impact on the potential treatment for obesity and it can help in curbing the impact of related diseases. BAM15 increases mitochondrial respiration and other sustained activity in major ways, it does not impact food consumption but reduces the influence of mitochondria.

In June 2020, Novo Nordisk declared the results of two clinical trials with a phase 2 monotherapy trial and a phase 1 combination trial of AM833, a novel once-weekly subcutaneous amylin analogue (AM833), and once-weekly subcutaneous semaglutide 2.4 mg. This test was conducted to understand obesity or overweight that have at least one weight-related comorbidity.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

 


aksharap

19 Blog posts

Comments